Stéphane Leprêtre Selected Research

Waldenstrom Macroglobulinemia (Macroglobulinemia)

11/2021

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stéphane Leprêtre Research Topics

Disease

14	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 06/2011
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2022 - 01/2018
4	Infections 07/2022 - 10/2009
4	Neoplasms (Cancer) 06/2022 - 05/2015
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 09/2015
3	Leukemia 01/2021 - 11/2018
2	Philadelphia Chromosome 01/2020 - 09/2015
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019 - 08/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2015 - 05/2013
2	Sarcopenia 07/2014 - 04/2014
1	Venous Thrombosis (Deep-Vein Thrombosis) 07/2022
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2022
1	Rheumatoid Arthritis 01/2022
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2021
1	Trisomy (Trisomies) 01/2020
1	Neutropenia 02/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Pancreatitis 09/2015
1	Hypersensitivity (Allergy) 09/2015
1	Febrile Neutropenia 05/2015
1	Cachexia 07/2014
1	Peritonitis 06/2014
1	Sepsis (Septicemia) 06/2014
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 05/2013
1	Residual Neoplasm 03/2012

Drug/Important Bio-Agent (IBA)

13	Rituximab (Mabthera)FDA Link 01/2022 - 03/2012
4	fludarabineIBA 01/2020 - 02/2016
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 02/2016
3	Biological ProductsIBA 01/2021 - 01/2019
2	Monoclonal AntibodiesIBA 01/2022 - 01/2017
2	Asparaginase (Elspar)FDA Link 01/2019 - 09/2015
2	Alemtuzumab (Campath)FDA Link 01/2018 - 03/2012
1	AntigensIBA 01/2022
1	idelalisibIBA 11/2021
1	obinutuzumabIBA 11/2021
1	Thymidine KinaseIBA 01/2020
1	ponatinibIBA 01/2020
1	Aspartate-Ammonia Ligase (Asparagine Synthetase)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2018
1	Cell-Free Nucleic AcidsIBA 01/2018
1	Cytokine Receptors (Cytokine Receptor)IBA 08/2017
1	Histones (Histone)IBA 08/2017
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	CD20 AntigensIBA 01/2017
1	Lipase (Acid Lipase)FDA Link 09/2015
1	PlatinumIBA 08/2015
1	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2015
1	Transcription Factors (Transcription Factor)IBA 06/2015
1	Dasatinib (BMS 354825)FDA Link 06/2015
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2015
1	Core Binding Factors (Core-Binding Factor)IBA 06/2015
1	Fluorine-18IBA 05/2015
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 05/2013
1	Purine NucleosidesIBA 03/2012
1	Pharmaceutical PreparationsIBA 10/2009

Therapy/Procedure

6	Therapeutics 06/2022 - 06/2015
4	Drug Therapy (Chemotherapy) 05/2015 - 04/2014
1	Vascular Access Devices (Arterial Line) 07/2022
1	Catheters 07/2022
1	Central Venous Catheters 05/2015
1	Immunotherapy 03/2012
1	Stem Cell Transplantation 06/2011